CNMD

CONMED Corp. 10-Q Summary: Quarter Ended June 30, 2026

Business Context and Reporting Period

CONMED Corporation (CNMD) is a medical technology company providing surgical devices and equipment for orthopedic and general surgery. This report covers the quarterly period ended June 30, 2026. The company operates as a single reporting segment with global sales. During the period, CONMED executed a strategic portfolio optimization, exiting its gastroenterology product offerings through asset sales and the termination of a distribution agreement with W.L. Gore & Associates, Inc.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Net sales were flat on a reported basis (+0.3% QoQ, -0.5% YoY for six months) but declined on a constant currency basis (-0.5% QoQ, -1.7% YoY for six months). Orthopedic surgery sales grew 8.2% (QoQ), while General surgery sales declined 5.2% (QoQ) due to the exit from gastroenterology products.
• Margins: Gross profit margins expanded 250 basis points to 57.5% (QoQ) and 57.7% (6mo YoY). This improvement was driven by an $8.5 million benefit from IEEPA tariff refunds and favorable product mix, partially offset by a $6.9 million charge for inventory and tooling discontinuation.
• Expenses: Selling and administrative expenses increased as a percentage of sales (42.4% vs. 39.7% prior year QoQ) due to a $4.4 million loss on the sale of gastroenterology assets, operational optimization costs, and advisory fees. R&D expenses increased 40 basis points to 4.5% of sales, driven by EU regulatory compliance costs.
• Debt Restructuring: The company repurchased $645.2 million of its 2.250% Convertible Notes for $637.2 million, recording an $8.1 million gain on extinguishment. Concurrently, it borrowed $450 million under a new Term A-2 Loan facility.

Outlook, Risks, and Unusual Items

• Unusual Items:
  • Asset Sales: Recorded a $4.4 million loss on the sale of gastroenterology assets (classified as a business) and a $1.9 million gain on the sale of other gastroenterology assets.
  • Tariff Refunds: Received $10.2 million in IEEPA tariff refunds, with $8.5 million recognized in Cost of Sales.
  • Debt Extinguishment: Recorded an $8.1 million gain on the repurchase of convertible notes, offset by $3.5 million in write-offs of unamortized debt issuance costs.
• Capital Allocation: The company suspended dividend payments to fund a $150 million share repurchase program. Approximately $43.7 million has been spent on repurchases through June 30, 2026. Management plans to repurchase at least $25 million annually.
• Risks: Key risks include supply chain challenges, inflationary pressures on manufacturing costs, foreign exchange volatility, and the impact of ongoing geopolitical conflicts (Ukraine/Middle East), though the company notes no material direct impact to date.

Investor Verification Checklist

• Debt Maturity Profile: Verify the repayment schedule for the remaining $153.9 million of 2.250% Convertible Notes maturing in June 2027 and the company's stated plan to fund this via operations and credit facilities.
• Dividend Policy: Confirm the status of the suspended dividend and the Board's timeline for potential reinstatement.
• Portfolio Optimization Impact: Assess the long-term revenue impact of the gastroenterology exit versus the growth in Orthopedic and General Surgery lines.
• Regulatory Compliance Costs: Monitor the trajectory of R&D expenses related to EU Medical Device Regulations.
• Share Repurchase Execution: Track the remaining $106.3 million available under the current repurchase program and the average price paid per share.